Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06593964

TACE With Thermosensitive Nanogel Versus Embosphere for HCC

To verify the safety and efficacy of TACE withThermosensitive Nanogel Embolic Agent for HCC.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year–80 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Gao-Jun Teng

Nanjing, China

Location status: Recruiting

Location contact

Gao-Jun Teng, MD

CONTACT

About this study

This is a prospective, multicenter, randomized controlled, non-inferiority design trial. Participants who meet the criteria will be randomly assigned into the experimental group or the control group,with a ratio of 1:1. In the experimental group the Thermosensitive Nanogel Embolic Agent will be used in the TACE procedure, while in the control group the Embosphere microspheres will be used. The primary endpoint is disease control rate of the target lesions at 1 month after the last TACE treatment.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Chinese Liver Cancer Staging Scheme, stage IIb-Illa, as well as those with stage Ia-Ila HCC, unsuitable or unwilling to undergo surgical resection, transplantation, or ablation;
  • Liver function status: Child-Pugh A or B
  • Eastern Cooperative Oncology Group score: 0-2 points;
  • With at least one measurable, unembolized liver tumor lesion (1-10 cm) ;
  • Willing to participate in this trial and sign the informed consent.

Exclusion criteria

  • The target lesion has been embolized before or require combined with other treatment(s);
  • Diffuse or with extrahepatic metastasis;
  • Coagulation dysfunction (PT prolonged beyond the upper limit of normal for 3 seconds);
  • Severe renal dysfunctions (creatinine clearance rate <30 ml/min);
  • Severe liver dysfunctions (alanine aminotransferase or aspartate aminotransferase exceeding the upper limit of normal by 5 times);
  • Main portal vein was completely occluded and no collateral blood supply was established;
  • With uncorrectable arteriovenous fistula or portal vein fistula;
  • Severe cachexia or hepatic encephalopathy;
  • With active infection;
  • Significant reductions in white blood cells or platelets (white blood cells<3.0x109/L, platelets<50x109/L) that cannot be corrected;
  • Pregnant or lactating women;
  • Difficulty in selective catheterization;
  • With the severe risk of non-target embolization;
  • Severely allergic to contrast agents or the embolic materials;
  • Participating in ongoing trial;
  • Unsuitable judged by the investigator.

Treatment and study plan

Thermosensitive Nanogel Embolic Agent

Device

Thermosensitive Nanogel Embolic Agent

Primary outcomes

  1. Disease control rate (DCR)

    Time frame: One month after the last TACE

    Probability of target lesion control, evaluated by the investigator and independent image review committee respectively (mRECIST).

Secondary outcomes

  1. Success rate of target lesion embolization

    Time frame: One month after the last TACE

    Success rate of target lesion embolization, evaluated by the investigator and independent image review committee respectively.

  2. Objective response rate (ORR)

    Time frame: One month after the last TACE treatment

    Objective response rate of target lesions, evaluated by the investigator and independent image review committee respectively (mRECIST).

  3. Disease control rate (DCR)

    Time frame: Three and six months after the first TACE

    Probability of target lesion control, evaluated by the investigator and independent image review committee respectively (mRECIST).

  4. Equipment performance evaluation

    Time frame: One month after the first TACE

    (Intraoperative imaging ability, microcatheter delivery capacity) evaluated by the investigator.

  5. Adverse events

    Time frame: Up to 24 months

    Rate of adverse events, evaluated by the investigator (CTACE 5.0)

Study contacts

Contact information is provided by the study sponsor or research team.

Lei Zhang, M.D.

CONTACT

[email protected]

+86 13770106862

Sponsors and collaborators

Lead sponsor

Zhongda Hospital

Other

Registry information

Official study title

Safety and Efficacy of TACE With Thermosensitive Nanogel Embolic Agent Versus Embosphere for Hepatocellular Carcinoma: A Prospective, Multicenter, Randomized Controlled, Non-inferiority Trial

Important dates

Study start
2024
Primary completion
2026
Study completion
2026
First posted
Sep 19, 2024
Registry last updated
Sep 19, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.